N/A N=141 Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients
Pulmonary Disease, Chronic Obstructive · Major Depression
Primary: Composite Antidepressant Score Scale (CAD) — 29; 25; 9; 20 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=56 COPD Assessment and Management Bundle Versus Usual Care
Chronic Obstructive Pulmonary Disease
Primary: Number of Participants With Accurate Classification of Irreversible Airflow Obstruction — 10; 5 Participants
N/A N=72 Acupuncture Treatment of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
COPD Exacerbation
Primary: Dyspnea Intensity — 8.0; 6.5; 7.75; 5 units on a scale
N/A N=1,507 Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants Who Received COPD Prescription for Maintenance Treatment at Baseline — 735; 68; 554; 105 Participants
Phase 3 N=738 Long-term Oxygen Treatment Trial
Chronic Obstructive Pulmonary Disease
Primary: Death or Hospitalization, Whichever Occurs First — 34.2; 36.4 Composite events/100 person-years — p=0.52
N/A N=1,371,146 Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study
Pulmonary Disease, Chronic Obstructive
Primary: Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US — 65.6; 64.4 Years
Phase 3 N=122 GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants
N/A N=3,954 Comparative Effectiveness of COPD Treatments
Pulmonary Disease, Chronic Obstructive
Primary: The Number of Observed Patients With First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation to Occur After Cohort Entry — 344; 412; 55; 60 Participants
N/A N=180 A Comprehensive Care Programme for Patients With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Hospital Readmission — 1.12; 1.7 hospital readmissions
Phase 4 N=318 Effectiveness of Antibiotic Therapy for Exacerbations of Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Number of Patients Who Were Cured — 91; 117 Participants — p=<0.05
N/A N=81 Effect of Increased Fruit and Vegetable Intake on Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Self-reported Intake of Fruit and Vegetables (Number of Portions Per Day); — 1.9; 6.1 Portions per day
Phase 4 N=1,670 Theophylline and Steroids in Chronic Obstructive Pulmonary Disease (COPD) Study
Chronic Obstructive Pulmonary Disease
Primary: Total COPD Exacerbation Rate — 1.00; 0.86; 0.89 Exacerbations per participant year
Phase 2 N=48 Effect of BIBW 2948 BS in COPD
Pulmonary Disease, Chronic Obstructive · Bronchitis, Chronic
Primary: Change From Baseline in Volume of Mucin Per Surface Area of Basal Lamina — 2.565; 1.180 micrometer^3/micrometer^2 — p=0.5305
Phase 2 N=10 Sildenafil for Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive · Emphysema
Primary: 6 Minute Walk Distance — 458.2; 466.1 meters
Phase 4 N=140 Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection
Pulmonary Disease, Chronic Obstructive
Primary: Trough FEV1 After 12 Weeks on Study Drug — 0.0378; 0.0947 Litre — p=0.3025
Phase 4 N=2,488 Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Time to First Moderate or Severe On-treatment COPD Exacerbation — 107.0; 110.0 days — p=0.3497
N/A N=8,853 Effectiveness of Triple Therapy in COPD
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants Hospitalised With Severe Exacerbation — 3074; 630 Participants
Phase 4 N=36 Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation
Chronic Obstructive Pulmonary Disease · COPD
Primary: Baseline Resting Cardiac Index (CI) — 2.4; 2.36 L/min/m^2 — p=0.85
Phase 1 N=9 Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Participants Who Experienced Safety Concerns, Where Safety Concerns of Quercetin Supplementation is Indicated by Significant Change From Baseline Measures of Tests…
Phase 2 N=101 A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) — 0.92; 0.95 AECOPD events/person-year — p=0.941
Phase 4 N=26 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)
CHRONIC OBSTRUCTIVE PULMONARY DISEASE · ASTHMA · HEALTHY SUBJECTS
Primary: ANALYSIS OF LUNG DEPOSITION - Penetration Index — 0.8; 0.72; 0.69; 0.58 ratio
Phase 2 N=405 Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients
COPD
Primary: Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4 — 0.203; 0.209; 0.257; 0.196 Liters — p=<0.001
Phase 2 N=28 The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose — 1.71; 1.79; 1.72; 1.71 L
N/A N=585 Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Clinical COPD Questionnaire (CCQ) Total Score Change From Baseline at Month 13 — -1.55 Units on a scale
Phase 2 N=62 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
COPD
Primary: Change From Baseline to Day 7 in Trough FEV1 (Forced Expiratory Volume in 1 Second) — 91.2; 92.8; 113.1; 151.9 FEV1 (mL)
N/A N=1,084 Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Participants Whose Post-albuterol Forced Expiratory Volume in One Second (FEV1) Was <80% Predicted Normal — 70; 30 percentage of participants
N/A N=182 Active for Life: Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Time Spent in Physical Activity as Measured by Upright Time (Minutes Per Day) Monitored by ActivPal Monitor — 278; 269; 293; 285 minutes per day
N/A N=1,142 Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Time Until First Occurrence of Acute Chronic Obstructive Pulmonary Disease (COPD) Exacerbation — 266; 174 Days
Phase 4 N=126 Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Inspiratory Capacity (IC) at Isotime — 0.0035; 0.07 liter — p=0.0087
Phase 3 N=304 To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways
Pulmonary Disease, Chronic Obstructive
Primary: Endurance Time During Endurance Shuttle Walk Test (ESWT) to Symptom Limitation After 8 Weeks — 244.07; 254.18; 315.32; 355.73 Second — p=0.0002